Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 251Lymphoma 241Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Leukemia 178Lymphoma, Large B-Cell, Diffuse 167Multiple Myeloma 166Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 146Leukemia, Myeloid, Acute 136Myelodysplastic Syndromes 116Hodgkin Disease 115Lymphoma, Follicular 113Burkitt Lymphoma 108Lymphoma, Mantle-Cell 104Lymphoma, B-Cell, Marginal Zone 76Lymphoma, Large-Cell, Immunoblastic 64Neoplasms, Plasma Cell 59Recurrence 58Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Myeloproliferative Disorders 53Neoplasms 49Leukemia, Myeloid, Chronic-Phase 49Triple Negative Breast Neoplasms 47Leukemia, Myeloid, Accelerated Phase 47Melanoma 46Leukemia, Myelomonocytic, Chronic 46Dendritic Cell Sarcoma, Interdigitating 46Waldenstrom Macroglobulinemia 42Hematologic Neoplasms 41Congenital Abnormalities 39

Interventions

pegfilgrastim 3NPI 2358 2pegylated granulocyte colony-stimulating factor 1Granulocyte Colony-Stimulating Factor 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Chemotherapy-induced Neutropenia × Cyclophosphamide × Clear all
NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡